Viking Therapeutics, Inc., was incorporated in Delaware on September 24, 2012. The company is a clinical-stage biopharmaceutical company dedicated to the development of new, first class or best class therapies for metabolic and endocrine disorders. The company has global exclusive rights to licence-based ligand small molecule combinations in five drug candidates in clinical trials or preclinical studies. The company's leading clinical program is VK 0612, an oral drug for the treatment of diabetes that has entered phase 2 b clinical trials as one of the world's largest health challenges for type 2, and it ranks first among the same drugs. The Company's second clinical program, vk 5211, delivers oral drug candidates into Phase 2 clinical trials for the treatment of uncontrolled muscle mass loss cancer cachexia characterized by a complex disease. VK 5211 is a non-steroidal selective androgen receptor modulator, or SARM.
